Solorank.ai
Login

Cached score snapshot

US.DVA · DaVita

110分制 53.5/110；5D動能v2 29/50；排序分 82.5/160 · Incomplete inputs

Back to ranking Open volume snapshot
Ranking score 82.5/160
Main score 53.5/110
5D momentum v2 29/50
Rank #12
Setup grade D 43.6

Score breakdown

避免

Medium twelvedata

Score and price trend

D 43.6 Money flow A · Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 06-22 08-04 09-16 10-07 10-27 $165.31$209.44$253.58 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.38 · anchors 120 -0.88% -1.98% / +1.34% 37.5% 5% Actual outcome pending · 0 / 3 bars observed
30D observation +2.33% -2.66% / +8.78% 61.3% 13.8% Actual outcome pending · 0 / 30 bars observed
Historical projection 10D n=160 -0.55% -2.15% / +1.45% 38.8% 6.9% Actual outcome pending · 0 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-06-22 → 2026-10-27 · 120 archived points · 2 Improving turn signal · 4 Deteriorating signal · 1 Exit review signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 82.5
Display grade 避免
Model version cursor_18_27_news_v2_160
Main score 53.5/110 (避免)
5D momentum v2 29/50 (中)
Score with momentum v2 82.5/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分，但以下輸入仍不完整；缺失維度以 0 分處理，請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 180.0755
ma50 203.2502
close 190.9
prevClose 189.32
avgVolume20 605705
volumeRatio 1.11
changePercent 0.83

Metrics snapshot

close 190.9
volume 673195
changePercent 0.83

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 53.5/110
Main rating 避免
5D momentum v2 29/50
Score with momentum v2 82.5/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 1.7/5 · 較差
Dimension score 1.7/5
Dimension grade 較差

Sub-items

pbPoints 0
pePoints 0.5
epsPoints 0
roePoints 0
debtPoints 0.3
marginPoints 0
turnoverUsdM 128.5129
volumePoints 0.5
revenuePoints 0
dividendPoints 0
marketCapPoints 0.4

資金流 — 15.6/20 · 良好
Dimension score 15.6/20
Dimension grade 良好

Sub-items

cmfPoints 1.6
mfiPoints 4
obvPoints 4
vwapPoints 4

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.DVA
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 4.6/15 · 較差
Dimension score 4.6/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 0.8

details

qqq

ma20 713.307
ma50 709.9724
name QQQ
close 704.54
points 0.4

spy

ma20 765.342
ma50 759.0606
name SPY
close 757.39
points 0.4
source twelvedata+fred
atrPct 2.6801
atrPoints 3
cciPoints 0.8
vixPoints 0
marketTrendPoints 0.8

催化劑 — 2/20 · 較差
Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 4
catalystCount 0
catalystPoints 2

風險管理 — 6.8/10 · 一般
Dimension score 6.8/10
Dimension grade 一般

Sub-items

position

score 1.4

details

atrPct 2.6801
turnoverUsdM 128.5129
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.6

stopLevels

symbol US.DVA
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 180.6672

strength_details

ma_score 1
atr_score 2
rsi_score 3
macd_score 2.5
volume_score 2
market_adjustment 1
risk_reward_ratio 1.6
stop_loss_percent 5.4
take_profit_price 206.8461
target_multiplier 2.2
technical_strength 2.13
take_profit_percent 8.4
positionPoints 1.4
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.5671
stopLossPercent 5.3603
diversificationPoints 2

技術信號 — 20.8/30 · 一般
Dimension score 20.8/30
Dimension grade 一般

Sub-items

bbPoints 3
adxPoints 3
sarPoints 2.4
vcpPoints 2.1
macdPoints 3.2

vcpPayload

vcp_pass false
vcp_score 2.1
vcp_reason 波幅收縮(39.9%→7.6%)；靠近20日高位；收盤突破20日高位；Ready=N；Confirm=Y

vcp_metrics

up_days 7
vol_ref 901323.3333
down_days 2
vcp_ready false
above_ma50 false
avg_vol_10 625350
avg_vol_20 597040
avg_vol_30 901323.3333
range_pct_10 0.0759
range_pct_20 0.0972
range_pct_30 0.3986
up_expand_ok false
lookback_used 59
near_20d_high true
contraction_ok true
down_shrink_ok false
up_expand_days 0
breakout_20d_ok true
vol_ratio_10_30 0.6938
dist_to_20d_high -0.005
down_shrink_days 2
breakout_level_20d 189.95
vcp_breakout_confirm true
contraction_ratio_10_30 0.1903
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction true
kdjAdxPoints 0.7
rsiKdjPoints 3.2
volumeWeight 2
maCrossPoints 0
shortRsiPoints 1
shortMacdPoints 0.4
volConfirmPoints 0.6
volumePointsTechnical 1.2

情緒分析 — 2/10 · 較差
Dimension score 2/10
Dimension grade 較差

Sub-items

sentiment

score 2

details

source finnhub_news_keyword_model
articleCount 4
negativeHits 0
positiveHits 0
sentimentScoreRaw 0

sentimentData

raw {"id":141951375,"url":"https://finnhub.io/api/news?id=00ceab943becc889852d59e6528dbe5cd56045d4404a62695d52b3afd9562a32","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"DaVita’s 20.6% return over the past six months has outpaced the S&P 500 by 7%, and its stock price has climbed to $183.98 per share. This performance may have investors wondering how to approach the situation.","category":"company","datetime":1788877398,"headline":"3 Reasons to Sell DVA and 1 Stock to Buy Instead"}, {"id":141423002,"url":"https://finnhub.io/api/news?id=5a680d055ddeb06d8e5ed20a8ec2f72d7a90a006a3aa38bc3fb209ea607b65ea","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"DaVita (DVA) is back in focus after two meaningful developments. The company expanded its value based care partnership with Humana for chronic kidney disease patients and agreed to a US$15 million settlement related to a prior data breach. Investors have been reacting to this mix of partnership news and legal resolution with a share price that is still up 58.64% year to date, despite a 30 day share price return of down 20.32%. The 3 year total shareholder return of 90.54% points to momentum...","category":"company","datetime":1788524025,"headline":"DaVita (DVA) Has Investors Asking A Fresh Question"}, {"id":141400633,"url":"https://finnhub.io/api/news?id=595b73bf89e80d13752af49c883469a8239d7018da51accdfc2ed2fe3801f203","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","category":"company","datetime":1788449411,"headline":"Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?"}, {"id":141365060,"url":"https://finnhub.io/api/news?id=a1473b28ba4a6835fe121a1d8f9ed05bd061c5d3cdc3db5ada00e563a05ec31c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.","category":"company","datetime":1787761620,"headline":"DVA & Humana Expand Value-Based Care for Kidney Disease Patients"}
raw_source {"id":142137539,"url":"https://finnhub.io/api/news?id=33ff5842b7d9838d33e6c7b265c8962c35a58346576a961ea3356d79391bd951","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"Paving Career Paths to Economic Mobility NORTHAMPTON, MA / ACCESS Newswire / September 14, 2026 / Sustainable career growth is about unlocking lasting economic mobility and new opportunities to learn and grow as an individual. In an evolving healthcare landscape, is working to empower teammates through intentional, comprehensive support.","category":"company","datetime":1789393200,"headline":"DaVita Community Care Report 2025: Empowering Teammates Through Career Development and Education"}, {"id":142061020,"url":"https://finnhub.io/api/news?id=fed805db3b7c95b9eccd66738bc0d4f9ffa5bd6c3a1cabcb470a95b8b17203f9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"NORTHAMPTON, MA / ACCESS Newswire / September 10, 2026 / 2025 marked a proud moment for as we met our goal to power 100% of our global operations with renewable energy. We achieved this by securing multiple virtual power purchase agreements in the US and Europe over the past five years - offsetting our global energy consumption with renewable solar and wind power.","category":"company","datetime":1789043700,"headline":"DaVita Community Care Report 2025: Our Journey to Net Zero"}, {"id":142026248,"url":"https://finnhub.io/api/news?id=3f5cd0fdb4515941bb771f71a8686240e99d400974d9617968a7b220f966a7b7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.","category":"company","datetime":1788969960,"headline":"Here's Why You Should Retain DaVita Stock in Your Portfolio for Now"}, {"id":141951375,"url":"https://finnhub.io/api/news?id=00ceab943becc889852d59e6528dbe5cd56045d4404a62695d52b3afd9562a32","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"DaVita’s 20.6% return over the past six months has outpaced the S&P 500 by 7%, and its stock price has climbed to $183.98 per share. This performance may have investors wondering how to approach the situation.","category":"company","datetime":1788877398,"headline":"3 Reasons to Sell DVA and 1 Stock to Buy Instead"}, {"id":141951376,"url":"https://finnhub.io/api/news?id=5572782c67ebdef0367850edba8336cb46165f767eb657063917040ebbde372a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"NORTHAMPTON, MA / ACCESS Newswire / September 8, 2026 / 's care network reaches people in every corner of the U. as well as 14 countries around the world.","category":"company","datetime":1788874500,"headline":"Commitment to Helping Communities Thrive: DaVita Community Care Report 2025"}, {"id":141447398,"url":"https://finnhub.io/api/news?id=d4fcb22ac911db4c29231c103d74684311f5617319035b806a7e28eaf68f2ed7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"NORTHAMPTON, MA / ACCESS Newswire / September 4, 2026 / At , doing the right thing and conducting business activities with the highest standards of ethics is foundational to our culture. We are firmly committed to compliance with our policies and all applicable laws and regulations.","category":"company","datetime":1788538800,"headline":"DaVita Community Care Report 2025: Leading With Integrity and Accountability"}, {"id":141438547,"url":"https://finnhub.io/api/news?id=e66244a112e47b56abc30df5a5ef3b3027d2500b2ad82a88abf1240bb4e19af8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","category":"company","datetime":1788535829,"headline":"Why Is Encompass Health (EHC) Down 1.8% Since Last Earnings Report?"}, {"id":141425454,"url":"https://finnhub.io/api/news?id=5b071eb4e00299b722c75d872bfe5a57448e129cf0f52d68bed0d9c9fc6234ad","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.","category":"company","datetime":1788526690,"headline":"3 of Wall Street’s Favorite Stocks We Find Risky"}, {"id":141423002,"url":"https://finnhub.io/api/news?id=5a680d055ddeb06d8e5ed20a8ec2f72d7a90a006a3aa38bc3fb209ea607b65ea","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"DaVita (DVA) is back in focus after two meaningful developments. The company expanded its value based care partnership with Humana for chronic kidney disease patients and agreed to a US$15 million settlement related to a prior data breach. Investors have been reacting to this mix of partnership news and legal resolution with a share price that is still up 58.64% year to date, despite a 30 day share price return of down 20.32%. The 3 year total shareholder return of 90.54% points to momentum...","category":"company","datetime":1788524025,"headline":"DaVita (DVA) Has Investors Asking A Fresh Question"}, {"id":141534513,"url":"https://finnhub.io/api/news?id=1dc0e132330bc351cae1d5760d0aafb2cba3b3b0bc94c3aeb5aa7c9e347fdec1","image":"https://cdn.benzinga.com/files/images/story/2026/09/04/Man-Using-Red-Holographic-Interface-Repr.jpg?width=2048&height=1536","source":"Benzinga","related":"DVA","summary":"A federal court preliminarily approves a class action settlement for 2.3 million patients affected by the DaVita ransomware attack.","category":"company","datetime":1788519390,"headline":"DaVita Reaches Preliminary Settlement Class Agreement Following Ransomware Attack"}, {"id":141403974,"url":"https://finnhub.io/api/news?id=747c2ac538ff0cdbcb6f69dec8f9c323aeeac34b9484336e5eea3f5545fe7f4c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.","category":"company","datetime":1788463320,"headline":"Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?"}, {"id":141400633,"url":"https://finnhub.io/api/news?id=595b73bf89e80d13752af49c883469a8239d7018da51accdfc2ed2fe3801f203","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","category":"company","datetime":1788449411,"headline":"Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?"}, {"id":141398580,"url":"https://finnhub.io/api/news?id=8be2f77d68f5d5ea4a0fb813bc79047deb4bbbcb33afcdc45eee1aba105c9f66","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"Investors need to pay close attention to DVA stock based on the movements in the options market lately.","category":"company","datetime":1788444000,"headline":"Do Options Traders Know Something About DaVita Stock We Don't?"}, {"id":141390281,"url":"https://finnhub.io/api/news?id=1c634fe655fd2d428d8c14d00428ce61c358195cde32344159635a5b6abc7918","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.","category":"company","datetime":1788377543,"headline":"1 Value Stock to Target This Week and 2 We Find Risky"}, {"id":141380019,"url":"https://finnhub.io/api/news?id=34048c4cac93b2047426f0fd7e7814a8044752812ba68ba628dbb0ef3fc0a1fb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"The dialysis provider has opted to settle a proposed class action lawsuit stemming from a data breach last year that impacted 2.7 million people.","category":"company","datetime":1788351793,"headline":"DaVita agrees to pay $15M to settle claims from data breach"}, {"id":141376765,"url":"https://finnhub.io/api/news?id=88927b1a09908d69df3de60404803940cd8cb8dfca67fd486303a41daffb558a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.","category":"company","datetime":1788347063,"headline":"1 Value Stock with Impressive Fundamentals and 2 Facing Headwinds"}, {"id":141365859,"url":"https://finnhub.io/api/news?id=8f314dfb87854390f75b4645f8c3e2afe37e61ffeac4b433944887edb177af6b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"Outpatient and home healthcare stocks gain from aging, digital care and AI, with LifeStance, Option Care, Aveanna and DaVita in focus.","category":"company","datetime":1788192060,"headline":"Zacks Industry Outlook Highlights DaVita, LifeStance Health, Option Care Health, and Aveanna Healthcare"}, {"id":141365861,"url":"https://finnhub.io/api/news?id=68d968e51b132d3b06478e9bce40f08e64a1abaf3598cef01bf92de6662c0391","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.","category":"company","datetime":1787935320,"headline":"4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds"}, {"id":141337962,"url":"https://finnhub.io/api/news?id=88430730e3bbe335c5c79b5b35e2bac53a635d97ecfcc966ade7946c4703fe0c","image":"https://cdn.benzinga.com/files/images/story/2026/08/28/The-Berkshire-Hathaway-Logo-Appears-On-A.jpg?width=2048&height=1536","source":"Benzinga","related":"DVA","summary":"Berkshire slashed its Capital One stake by 58%, among its largest cuts, despite the stock's top growth score.","category":"company","datetime":1787897798,"headline":"Berkshire Hathaway Cut Capital One Stake by 58% in Q2 — Billionaire Dan Loeb Is Doing the Exact Opposite"}, {"id":141362279,"url":"https://finnhub.io/api/news?id=24b0483fb4d23d2a45eae08e6d6541aacc916e096a9d26974d4a6b6bfd7da4cf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"CVS Health carries strong pharmacy momentum into H2 2026, with rising prescription volume, Rite Aid gains and higher profit.","category":"company","datetime":1787846340,"headline":"How CVS' Pharmacy & Consumer Wellness Is Positioned for H2 2026"}, {"id":141365060,"url":"https://finnhub.io/api/news?id=a1473b28ba4a6835fe121a1d8f9ed05bd061c5d3cdc3db5ada00e563a05ec31c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.","category":"company","datetime":1787761620,"headline":"DVA & Humana Expand Value-Based Care for Kidney Disease Patients"}, {"id":141365865,"url":"https://finnhub.io/api/news?id=3141d3816274b52375de647bc349cdb27536a74a8125e7e75918305bab46d688","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"Alebund Pharmaceuticals (Jiangsu) Limited (\"Alebund\" or the \"Company\"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the \"Reporting Period\"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.","category":"company","datetime":1787745540,"headline":"Alebund Pharmaceuticals Announces 2026 Interim Results"}, {"id":141363997,"url":"https://finnhub.io/api/news?id=113b739abd66042c9c6f4a01976044dea0bba3744bc7821551df70bc43445128","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"Humana stock has delivered a strong 46.2% return year to date, yet the valuation checks paint a mixed picture that leaves investors weighing how much of the story is already reflected in the price. Year to date, Humana is up 46.2%, which puts recent gains front and centre for anyone assessing what the current valuation implies. Recent moves such as the value based partnership with DaVita and the appointment of a new Chief Medical Officer may support confidence in Humana's care model and...","category":"company","datetime":1787692378,"headline":"Can Humana (HUM) Stay Cheap If Medicare Advantage Margins Tighten?"}, {"id":141363998,"url":"https://finnhub.io/api/news?id=a22c7adae1e24ce140ae7494bf0247e1d208d4f69aeec0569d564f567b9c6401","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"DaVita (NYSE:DVA) has expanded its partnership with Humana (NYSE:HUM) through a new value-based care agreement covering more than 10,000 Medicare Advantage members living with chronic kidney disease. The programme, which launched on July 1, targets patients with stages 3B through 5 chronic kidney disease (CKD).","category":"company","datetime":1787659638,"headline":"DaVita and Humana Expand Kidney Care Partnership to More Than 10,000 Patients"}, {"id":141365866,"url":"https://finnhub.io/api/news?id=1120399ed650c4b2cea8b24748973cccfa028a28c27ce5b38c9edec75f5d6061","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"DaVita today announced a new value-based care agreement to deliver comprehensive, coordinated care to Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5.","category":"company","datetime":1787655600,"headline":"DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease"}, {"id":141318607,"url":"https://finnhub.io/api/news?id=a4c2baebf2d01b5799e24966e573c7430250e8ea208b793e054ffcb1486afeaf","image":"","source":"Benzinga","related":"DVA","summary":"Launched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the greatest impact.As","category":"company","datetime":1787638363,"headline":"DaVita Enters Value-Based Care Agreement With Humana Medicare Advantage To Provide Care To Members With Chronic Kidney Disease Stages 3B–5"}, {"id":141286519,"url":"https://finnhub.io/api/news?id=67f152bf561809429a189bf7214a935dfbcaace2e158b7564e8e3697cae69a22","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DVA","summary":"NORTHAMPTON, MA / ACCESS Newswire / August 18, 2026 / Throughout DaVita's 25+ year history, we've led the way in patient-centered kidney care. Our work has played a key role in reducing hospitalizations, extending lifespan and helping propel the kidney ...","category":"company","datetime":1787063700,"headline":"Forever Committed to Excellence in Care: DaVita Community Care Report 2025"}
data_source finnhub_news_keyword_model
article_count 4
negative_hits 0
positive_hits 0
recomputed_at_score true
sentiment_score_raw 0
source_article_count 27
discarded_article_count 23
sentimentPoints 2

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 1.7 5/110 34% 1.7
資金流 15.6 20/110 78% 15.6
市場環境 4.6 15/110 30.67% 4.6
催化劑 2 20/110 10% 2
風險管理 6.8 10/110 68% 6.8
技術信號 20.8 30/110 69.33% 20.8
情緒分析 2 10/110 20% 2

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 29/50
ret_5d 0.0602
max_score 50
max_total 50
raw_total 29
vcp_bonus 0
vol_ratio 1.1276
ret_points 12
vol_points 2
range_ratio 1.0913
volat_points 0
day_range_pct 0.0265
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 8
partial_history false
pullback_points 3
breakout_vol_bonus 0
first_breakout_20d true
return_window_days 5
first_breakout_bonus 2
breakout_quality_points 2

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.4

details

atrPct 2.6801
turnoverUsdM 128.5129
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.6

stopLevels

symbol US.DVA
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 180.6672

strength_details

ma_score 1
atr_score 2
rsi_score 3
macd_score 2.5
volume_score 2
market_adjustment 1
risk_reward_ratio 1.6
stop_loss_percent 5.4
take_profit_price 206.8461
target_multiplier 2.2
technical_strength 2.13
take_profit_percent 8.4
positionPoints 1.4
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.5671
stopLossPercent 5.3603
diversificationPoints 2

Calculation audit log

基本面分析總分: 1.7/5分
資金流分析總分: 15.6/20分
市場環境分析總分: 4.6/15分
催化劑分析: 2/20分
風險管理總分: 6.8/10分
技術信號分析總分: 20.8/30分
情緒分析: 2/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 78.57
atr
atr 5.1164
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.68
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value 216.88
cmf
rule Cursor_18.24 CMF bands
level 平衡
score 4
value 0.0214
kdj
d 75.21
j 99.29
k 83.23
rule Cursor_18.24 K/D cross
score 4
signal 金叉
mfi
rule Cursor_18.24 MFI bands
level 強資金流入
score 10
value 72.44
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 10
trend 強流入
value 3848795
recentSlope 330699.5
previousSlope 75680
rsi
value 68.19
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 177.4503
position SAR喺價下
distancePct 7.05
previousTrend 上升
ma50
value 203.2502
macd
macd -3.2267
trend 看漲
signal -6.0989
histogram 2.8722
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 10
value 179.9005
position 連續5日>VWAP
consecutiveAbove 9
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.11
score 6
avgVolume 605705
currentVolume 673195
derived
ma20 180.0755
ma50 203.2502
prevClose 189.32
avgVolume10 635280
avgVolume20 605705
changePercent 0.83
avgVolumeForScore 605705
ma_cross
ma20 180.0755
ma50 203.2502
rule Cursor_18.24 MA20/MA50 cross
cross 熊勢
score 0
prevMa20 179.3655
prevMa50 204.1464
spreadPct 11.4
isVolumeBreakout false
bollinger
lower 171.5886
upper 188.5624
position 上半部
rsi_short
value 69.06
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.11

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.680146814046454,
        "turnoverUsdM": 128.51291876805,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.6,
    "stopLevels": {
      "symbol": "US.DVA",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 180.6672,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 2.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.6,
      "stop_loss_percent": 5.4,
      "take_profit_price": 206.8461,
      "target_multiplier": 2.2,
      "technical_strength": 2.13,
      "take_profit_percent": 8.4
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.567078332421234,
    "stopLossPercent": 5.360293628092908,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 82.5,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 53.5,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 29
  },
  "market": {
    "ma20": 180.0755,
    "ma50": 203.2502,
    "close": 190.9,
    "prevClose": 189.32,
    "avgVolume20": 605705,
    "volumeRatio": 1.11,
    "changePercent": 0.83
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 29,
    "details": {
      "ret_5d": 0.06020211107633133,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 29,
      "vcp_bonus": 0,
      "vol_ratio": 1.1275542677207557,
      "ret_points": 12,
      "vol_points": 2,
      "range_ratio": 1.0912628348414644,
      "volat_points": 0,
      "day_range_pct": 0.02645364203528775,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 8,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": true,
      "return_window_days": 5,
      "first_breakout_bonus": 2,
      "breakout_quality_points": 2
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 82.5,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 1.7,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 34,
        "contribution": 1.7
      },
      {
        "raw": 15.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 78,
        "contribution": 15.6
      },
      {
        "raw": 4.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 30.67,
        "contribution": 4.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 68,
        "contribution": 6.8
      },
      {
        "raw": 20.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 69.33,
        "contribution": 20.8
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 53.5,
    "details": [
      "基本面分析總分: 1.7/5分",
      "資金流分析總分: 15.6/20分",
      "市場環境分析總分: 4.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.8/10分",
      "技術信號分析總分: 20.8/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 1.7,
      "資金流": 15.6,
      "市場環境": 4.6,
      "情緒分析": 2,
      "技術信號": 20.8,
      "風險管理": 6.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 4,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0,
          "pePoints": 0.5,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.3,
          "marginPoints": 0,
          "turnoverUsdM": 128.51291876805,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.DVA",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 713.30699735,
                "ma50": 709.9723986999998,
                "name": "QQQ",
                "close": 704.53998,
                "points": 0.4
              },
              "spy": {
                "ma20": 765.34199445,
                "ma50": 759.0606000200002,
                "name": "SPY",
                "close": 757.39001,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.680146814046454,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 4,
              "negativeHits": 0,
              "positiveHits": 0,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141951375,
                "url": "https://finnhub.io/api/news?id=00ceab943becc889852d59e6528dbe5cd56045d4404a62695d52b3afd9562a32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita’s 20.6% return over the past six months has outpaced the S&P 500 by 7%, and its stock price has climbed to $183.98 per share. This performance may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1788877398,
                "headline": "3 Reasons to Sell DVA and 1 Stock to Buy Instead"
              },
              {
                "id": 141423002,
                "url": "https://finnhub.io/api/news?id=5a680d055ddeb06d8e5ed20a8ec2f72d7a90a006a3aa38bc3fb209ea607b65ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita (DVA) is back in focus after two meaningful developments. The company expanded its value based care partnership with Humana for chronic kidney disease patients and agreed to a US$15 million settlement related to a prior data breach. Investors have been reacting to this mix of partnership news and legal resolution with a share price that is still up 58.64% year to date, despite a 30 day share price return of down 20.32%. The 3 year total shareholder return of 90.54% points to momentum...",
                "category": "company",
                "datetime": 1788524025,
                "headline": "DaVita (DVA) Has Investors Asking A Fresh Question"
              },
              {
                "id": 141400633,
                "url": "https://finnhub.io/api/news?id=595b73bf89e80d13752af49c883469a8239d7018da51accdfc2ed2fe3801f203",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449411,
                "headline": "Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?"
              },
              {
                "id": 141365060,
                "url": "https://finnhub.io/api/news?id=a1473b28ba4a6835fe121a1d8f9ed05bd061c5d3cdc3db5ada00e563a05ec31c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.",
                "category": "company",
                "datetime": 1787761620,
                "headline": "DVA & Humana Expand Value-Based Care for Kidney Disease Patients"
              }
            ],
            "raw_source": [
              {
                "id": 142137539,
                "url": "https://finnhub.io/api/news?id=33ff5842b7d9838d33e6c7b265c8962c35a58346576a961ea3356d79391bd951",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Paving Career Paths to Economic Mobility NORTHAMPTON, MA / ACCESS Newswire / September 14, 2026 / Sustainable career growth is about unlocking lasting economic mobility and new opportunities to learn and grow as an individual. In an evolving healthcare landscape, is working to empower teammates through intentional, comprehensive support.",
                "category": "company",
                "datetime": 1789393200,
                "headline": "DaVita Community Care Report 2025: Empowering Teammates Through Career Development and Education"
              },
              {
                "id": 142061020,
                "url": "https://finnhub.io/api/news?id=fed805db3b7c95b9eccd66738bc0d4f9ffa5bd6c3a1cabcb470a95b8b17203f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "NORTHAMPTON, MA / ACCESS Newswire / September 10, 2026 / 2025 marked a proud moment for as we met our goal to power 100% of our global operations with renewable energy. We achieved this by securing multiple virtual power purchase agreements in the US and Europe over the past five years - offsetting our global energy consumption with renewable solar and wind power.",
                "category": "company",
                "datetime": 1789043700,
                "headline": "DaVita Community Care Report 2025: Our Journey to Net Zero"
              },
              {
                "id": 142026248,
                "url": "https://finnhub.io/api/news?id=3f5cd0fdb4515941bb771f71a8686240e99d400974d9617968a7b220f966a7b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.",
                "category": "company",
                "datetime": 1788969960,
                "headline": "Here's Why You Should Retain DaVita Stock in Your Portfolio for Now"
              },
              {
                "id": 141951375,
                "url": "https://finnhub.io/api/news?id=00ceab943becc889852d59e6528dbe5cd56045d4404a62695d52b3afd9562a32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita’s 20.6% return over the past six months has outpaced the S&P 500 by 7%, and its stock price has climbed to $183.98 per share. This performance may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1788877398,
                "headline": "3 Reasons to Sell DVA and 1 Stock to Buy Instead"
              },
              {
                "id": 141951376,
                "url": "https://finnhub.io/api/news?id=5572782c67ebdef0367850edba8336cb46165f767eb657063917040ebbde372a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "NORTHAMPTON, MA / ACCESS Newswire / September 8, 2026 / 's care network reaches people in every corner of the U. as well as 14 countries around the world.",
                "category": "company",
                "datetime": 1788874500,
                "headline": "Commitment to Helping Communities Thrive: DaVita Community Care Report 2025"
              },
              {
                "id": 141447398,
                "url": "https://finnhub.io/api/news?id=d4fcb22ac911db4c29231c103d74684311f5617319035b806a7e28eaf68f2ed7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "NORTHAMPTON, MA / ACCESS Newswire / September 4, 2026 / At , doing the right thing and conducting business activities with the highest standards of ethics is foundational to our culture. We are firmly committed to compliance with our policies and all applicable laws and regulations.",
                "category": "company",
                "datetime": 1788538800,
                "headline": "DaVita Community Care Report 2025: Leading With Integrity and Accountability"
              },
              {
                "id": 141438547,
                "url": "https://finnhub.io/api/news?id=e66244a112e47b56abc30df5a5ef3b3027d2500b2ad82a88abf1240bb4e19af8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535829,
                "headline": "Why Is Encompass Health (EHC) Down 1.8% Since Last Earnings Report?"
              },
              {
                "id": 141425454,
                "url": "https://finnhub.io/api/news?id=5b071eb4e00299b722c75d872bfe5a57448e129cf0f52d68bed0d9c9fc6234ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.",
                "category": "company",
                "datetime": 1788526690,
                "headline": "3 of Wall Street’s Favorite Stocks We Find Risky"
              },
              {
                "id": 141423002,
                "url": "https://finnhub.io/api/news?id=5a680d055ddeb06d8e5ed20a8ec2f72d7a90a006a3aa38bc3fb209ea607b65ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita (DVA) is back in focus after two meaningful developments. The company expanded its value based care partnership with Humana for chronic kidney disease patients and agreed to a US$15 million settlement related to a prior data breach. Investors have been reacting to this mix of partnership news and legal resolution with a share price that is still up 58.64% year to date, despite a 30 day share price return of down 20.32%. The 3 year total shareholder return of 90.54% points to momentum...",
                "category": "company",
                "datetime": 1788524025,
                "headline": "DaVita (DVA) Has Investors Asking A Fresh Question"
              },
              {
                "id": 141534513,
                "url": "https://finnhub.io/api/news?id=1dc0e132330bc351cae1d5760d0aafb2cba3b3b0bc94c3aeb5aa7c9e347fdec1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/04/Man-Using-Red-Holographic-Interface-Repr.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "DVA",
                "summary": "A federal court preliminarily approves a class action settlement for 2.3 million patients affected by the DaVita ransomware attack.",
                "category": "company",
                "datetime": 1788519390,
                "headline": "DaVita Reaches Preliminary Settlement Class Agreement Following Ransomware Attack"
              },
              {
                "id": 141403974,
                "url": "https://finnhub.io/api/news?id=747c2ac538ff0cdbcb6f69dec8f9c323aeeac34b9484336e5eea3f5545fe7f4c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.",
                "category": "company",
                "datetime": 1788463320,
                "headline": "Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?"
              },
              {
                "id": 141400633,
                "url": "https://finnhub.io/api/news?id=595b73bf89e80d13752af49c883469a8239d7018da51accdfc2ed2fe3801f203",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449411,
                "headline": "Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?"
              },
              {
                "id": 141398580,
                "url": "https://finnhub.io/api/news?id=8be2f77d68f5d5ea4a0fb813bc79047deb4bbbcb33afcdc45eee1aba105c9f66",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Investors need to pay close attention to DVA stock based on the movements in the options market lately.",
                "category": "company",
                "datetime": 1788444000,
                "headline": "Do Options Traders Know Something About DaVita Stock We Don't?"
              },
              {
                "id": 141390281,
                "url": "https://finnhub.io/api/news?id=1c634fe655fd2d428d8c14d00428ce61c358195cde32344159635a5b6abc7918",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.",
                "category": "company",
                "datetime": 1788377543,
                "headline": "1 Value Stock to Target This Week and 2 We Find Risky"
              },
              {
                "id": 141380019,
                "url": "https://finnhub.io/api/news?id=34048c4cac93b2047426f0fd7e7814a8044752812ba68ba628dbb0ef3fc0a1fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "The dialysis provider has opted to settle a proposed class action lawsuit stemming from a data breach last year that impacted 2.7 million people.",
                "category": "company",
                "datetime": 1788351793,
                "headline": "DaVita agrees to pay $15M to settle claims from data breach"
              },
              {
                "id": 141376765,
                "url": "https://finnhub.io/api/news?id=88927b1a09908d69df3de60404803940cd8cb8dfca67fd486303a41daffb558a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.",
                "category": "company",
                "datetime": 1788347063,
                "headline": "1 Value Stock with Impressive Fundamentals and 2 Facing Headwinds"
              },
              {
                "id": 141365859,
                "url": "https://finnhub.io/api/news?id=8f314dfb87854390f75b4645f8c3e2afe37e61ffeac4b433944887edb177af6b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Outpatient and home healthcare stocks gain from aging, digital care and AI, with LifeStance, Option Care, Aveanna and DaVita in focus.",
                "category": "company",
                "datetime": 1788192060,
                "headline": "Zacks Industry Outlook Highlights DaVita, LifeStance Health, Option Care Health, and Aveanna Healthcare"
              },
              {
                "id": 141365861,
                "url": "https://finnhub.io/api/news?id=68d968e51b132d3b06478e9bce40f08e64a1abaf3598cef01bf92de6662c0391",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.",
                "category": "company",
                "datetime": 1787935320,
                "headline": "4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds"
              },
              {
                "id": 141337962,
                "url": "https://finnhub.io/api/news?id=88430730e3bbe335c5c79b5b35e2bac53a635d97ecfcc966ade7946c4703fe0c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/28/The-Berkshire-Hathaway-Logo-Appears-On-A.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "DVA",
                "summary": "Berkshire slashed its Capital One stake by 58%, among its largest cuts, despite the stock's top growth score.",
                "category": "company",
                "datetime": 1787897798,
                "headline": "Berkshire Hathaway Cut Capital One Stake by 58% in Q2 — Billionaire Dan Loeb Is Doing the Exact Opposite"
              },
              {
                "id": 141362279,
                "url": "https://finnhub.io/api/news?id=24b0483fb4d23d2a45eae08e6d6541aacc916e096a9d26974d4a6b6bfd7da4cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "CVS Health carries strong pharmacy momentum into H2 2026, with rising prescription volume, Rite Aid gains and higher profit.",
                "category": "company",
                "datetime": 1787846340,
                "headline": "How CVS' Pharmacy & Consumer Wellness Is Positioned for H2 2026"
              },
              {
                "id": 141365060,
                "url": "https://finnhub.io/api/news?id=a1473b28ba4a6835fe121a1d8f9ed05bd061c5d3cdc3db5ada00e563a05ec31c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.",
                "category": "company",
                "datetime": 1787761620,
                "headline": "DVA & Humana Expand Value-Based Care for Kidney Disease Patients"
              },
              {
                "id": 141365865,
                "url": "https://finnhub.io/api/news?id=3141d3816274b52375de647bc349cdb27536a74a8125e7e75918305bab46d688",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Alebund Pharmaceuticals (Jiangsu) Limited (\"Alebund\" or the \"Company\"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the \"Reporting Period\"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.",
                "category": "company",
                "datetime": 1787745540,
                "headline": "Alebund Pharmaceuticals Announces 2026 Interim Results"
              },
              {
                "id": 141363997,
                "url": "https://finnhub.io/api/news?id=113b739abd66042c9c6f4a01976044dea0bba3744bc7821551df70bc43445128",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Humana stock has delivered a strong 46.2% return year to date, yet the valuation checks paint a mixed picture that leaves investors weighing how much of the story is already reflected in the price. Year to date, Humana is up 46.2%, which puts recent gains front and centre for anyone assessing what the current valuation implies. Recent moves such as the value based partnership with DaVita and the appointment of a new Chief Medical Officer may support confidence in Humana's care model and...",
                "category": "company",
                "datetime": 1787692378,
                "headline": "Can Humana (HUM) Stay Cheap If Medicare Advantage Margins Tighten?"
              },
              {
                "id": 141363998,
                "url": "https://finnhub.io/api/news?id=a22c7adae1e24ce140ae7494bf0247e1d208d4f69aeec0569d564f567b9c6401",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita (NYSE:DVA) has expanded its partnership with Humana (NYSE:HUM) through a new value-based care agreement covering more than 10,000 Medicare Advantage members living with chronic kidney disease. The programme, which launched on July 1, targets patients with stages 3B through 5 chronic kidney disease (CKD).",
                "category": "company",
                "datetime": 1787659638,
                "headline": "DaVita and Humana Expand Kidney Care Partnership to More Than 10,000 Patients"
              },
              {
                "id": 141365866,
                "url": "https://finnhub.io/api/news?id=1120399ed650c4b2cea8b24748973cccfa028a28c27ce5b38c9edec75f5d6061",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita today announced a new value-based care agreement to deliver comprehensive, coordinated care to Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5.",
                "category": "company",
                "datetime": 1787655600,
                "headline": "DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease"
              },
              {
                "id": 141318607,
                "url": "https://finnhub.io/api/news?id=a4c2baebf2d01b5799e24966e573c7430250e8ea208b793e054ffcb1486afeaf",
                "image": "",
                "source": "Benzinga",
                "related": "DVA",
                "summary": "Launched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the greatest impact.As",
                "category": "company",
                "datetime": 1787638363,
                "headline": "DaVita Enters Value-Based Care Agreement With Humana Medicare Advantage To Provide Care To Members With Chronic Kidney Disease Stages 3B–5"
              },
              {
                "id": 141286519,
                "url": "https://finnhub.io/api/news?id=67f152bf561809429a189bf7214a935dfbcaace2e158b7564e8e3697cae69a22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "NORTHAMPTON, MA / ACCESS Newswire / August 18, 2026 / Throughout DaVita's 25+ year history, we've led the way in patient-centered kidney care. Our work has played a key role in reducing hospitalizations, extending lifespan and helping propel the kidney ...",
                "category": "company",
                "datetime": 1787063700,
                "headline": "Forever Committed to Excellence in Care: DaVita Community Care Report 2025"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 4,
            "negative_hits": 0,
            "positive_hits": 0,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 27,
            "discarded_article_count": 23
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.8,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.1,
          "macdPoints": 3.2,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.1,
            "vcp_reason": "波幅收縮(39.9%→7.6%)；靠近20日高位；收盤突破20日高位；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 7,
              "vol_ref": 901323.3333333334,
              "down_days": 2,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 625350,
              "avg_vol_20": 597040,
              "avg_vol_30": 901323.3333333334,
              "range_pct_10": 0.0758512349843496,
              "range_pct_20": 0.0971713513447538,
              "range_pct_30": 0.3985857725817587,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 0,
              "breakout_20d_ok": true,
              "vol_ratio_10_30": 0.6938131710041161,
              "dist_to_20d_high": -0.005001263490392282,
              "down_shrink_days": 2,
              "breakout_level_20d": 189.95,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.19030090937024313
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 3.2,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.680146814046454,
              "turnoverUsdM": 128.51291876805,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.6,
          "stopLevels": {
            "symbol": "US.DVA",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 180.6672,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 2.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.6,
            "stop_loss_percent": 5.4,
            "take_profit_price": 206.8461,
            "target_multiplier": 2.2,
            "technical_strength": 2.13,
            "take_profit_percent": 8.4
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.567078332421234,
          "stopLossPercent": 5.360293628092908,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.DVA",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 5.1164,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.68
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 216.88
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0214
    },
    "kdj": {
      "d": 75.21,
      "j": 99.29,
      "k": 83.23,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 72.44
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 3848795,
      "recentSlope": 330699.5,
      "previousSlope": 75680
    },
    "rsi": 68.19,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 177.4503,
      "position": "SAR喺價下",
      "distancePct": 7.05,
      "previousTrend": "上升"
    },
    "ma50": 203.2502,
    "macd": {
      "macd": -3.226693199523055,
      "trend": "看漲",
      "signal": -6.098852386432011,
      "histogram": 2.8721591869089558
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 179.9005,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 9
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.11,
      "score": 6,
      "avgVolume": 605705,
      "currentVolume": 673195
    },
    "derived": {
      "ma20": 180.0755,
      "ma50": 203.2502,
      "prevClose": 189.32,
      "avgVolume10": 635280,
      "avgVolume20": 605705,
      "changePercent": 0.83,
      "avgVolumeForScore": 605705
    },
    "ma_cross": {
      "ma20": 180.0755,
      "ma50": 203.2502,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 179.3655,
      "prevMa50": 204.1464,
      "spreadPct": 11.4,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 171.5886,
      "upper": 188.5624,
      "position": "上半部"
    },
    "rsi_short": 69.06,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.11
    }
  }
}

Raw metrics JSON

 
{
  "close": 190.9,
  "volume": 673195,
  "changePercent": 0.83
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.